Advertisement
U.S. markets open in 1 hour 1 minute
S&P Futures
6,020.25 +13.75 (+0.23%) Dow Futures
44,720.00 -106.00 (-0.24%) Nasdaq Futures
20,934.50 +54.25 (+0.26%) Russell 2000 Futures
2,446.60 -4.40 (-0.18%) Crude Oil
69.51 +0.57 (+0.83%) Gold
2,640.10 +21.60 (+0.82%)
CytomX Therapeutics Inc (6C1.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Follow
As of 02:05PM CET. Market open.
| Previous Close | 0.9210 |
| Open | 0.9090 |
| Bid | 0.7870 x N/A |
| Ask | 1.0120 x N/A |
| Day's Range | 0.9005 - 0.9090 |
| 52 Week Range | 0.7965 - 4.5320 |
| Volume | |
| Avg. Volume | 15 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksJAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
- Zacks
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.